Greif, Inc. GEF

Key data

The business

Greif makes the industrial containers that carry liquids and powders: steel drums, plastic jerrycans and drums, and the large intermediate bulk containers strapped to pallets outside a chemical plant. Its customers are the makers of chemicals, coatings, lubricants, food ingredients and farm products, who fill those containers and ship them on. In August 2025 Greif sold its old containerboard and paper operation, and what is left is a cleaner, pure-play packaging company with a fraction of the debt it used to carry. The moat is ordinary but real: these are low-value, heavy, hard-to-ship products, so the maker with a plant near the customer wins on freight cost, and Greif has that plant network across dozens of countries. Demand tracks industrial production, which makes it cyclical, and the last two years have been the down part of the cycle.

The numbers

The story is a profit trough turning up hard.

The bottom was the quarter reported last December, a penny of profit, when customer destocking was at its worst and Greif missed by a mile. Two quarters later it earned $1.61 against the $1.11 modeled, the second straight beat and the sharpest, with volumes firming and margins holding. The rate of change is the whole point: not just higher, but accelerating off a floor.

That is the cycle in five rows: a FY22 peak near $621M of operating income, then two years grinding down to $338M as industrial demand softened. FY25 net income looks enormous only because it carries a large one-time gain from selling the paper business, which is exactly the figure distorting the trailing multiple today.

At $85 the stock screens under five times trailing earnings, which is why value screens flag it. That number is a mirage: trailing profit is swollen by the one-time divestiture gain, which will not repeat. On the earnings the business actually makes, the Street sees about $4.31 this fiscal year and $4.77 next, so you pay close to twenty times this year and 17.8 times next, against rivals near sixteen. The variant is narrow. The market that reads "5x" is wrong; the market that has normalized is paying a full price for a cyclical recovery, not a discount. The print that settles it is fiscal-fourth-quarter free cash flow: management guided to about 50% conversion for the year, and Q3 already turned $58M of adjusted free cash, so a clean Q4 that pulls trailing cash flow back above zero is the case for owning it in one number.

Management

Insiders have been sellers, and not quietly. CEO Ole Rosgaard sold about $3.5M of stock in early August, and CFO Larry Hilsheimer another $3.7M across two days the same week; against $2.0M of buys over the year, the ratio is lopsided, and the filings do not disclose plan status, so read it as conviction rather than calendar. On the other side, the record shows discipline: they used divestiture cash to cut long-term debt by roughly three-quarters, bought back $128M of stock in the period, and have kept raising the dividend. The two most recent quarters beat; the two before missed badly. This is a team that delivered the balance-sheet cleanup and is now being paid, personally, into the recovery it is selling.

How it fails or surprises you

Cash flow stays underwater. Trailing operating cash flow is negative and free cash flow is about minus 6% of market value, because Greif deliberately built high-cost inventory through the Middle East supply scare. Management says both normalize by fiscal Q4. If the December cash flow statement still shows a drain, the inventory was a demand misread, not a hedge, and the recovery thesis cracks.

Destocking does not actually end. The margin line held: trailing gross margin is 22.8%, just above the 22.5% mark that separates recovery from stall, and Q3 volumes firmed. But the confirming read, December's segment volume commentary, has not printed. If management again talks "continued softness" without a hard unit number, the turn everyone is now paying 17.8 times earnings for is bending.

Volumes snap back faster than priced (right tail). Greif's plants carry high fixed cost, so a genuine restock in chemicals and coatings drops almost straight to margin. Operating income ran above $600M at the last peak against $338M in FY24. If industrial demand normalizes into 2027 on a now-clean balance sheet, earnings power sits well above the $4.77 modeled, and the multiple compresses on its own.

Closing thoughts

The market already has a view and the edge is thin. The value screens see five times earnings and buy the headline; the careful money has stripped out the divestiture gain and is paying a full, slightly rich multiple for a cyclical that is genuinely turning. On real earnings near twenty times, you are not handed a discount, you are asked to underwrite the recovery at fair value, with a debt-free balance sheet as the margin of safety. The fatter tail is probably up, because operating leverage off a trough is powerful and the debt is gone, but the near-term risk is concrete: cash flow is negative today, and a December print that does not fix it turns "cheap cyclical" into "expensive one."

The bet is still that chemical, food and paint makers refill their shelves with Greif's drums and jugs, and that the order slump is ending rather than the new normal. What breaks it is a fourth-quarter cash flow statement that stays negative while management hedges on volumes; the pair to watch is free cash flow conversion against gross margin, and if conversion misses 50% while margin slips back under 22.5%, the recovery you paid 17.8 times earnings for was never there.